Home
Scholarly Works
900P Phase II study of individualized sunitinib...
Conference

900P Phase II study of individualized sunitinib (SUN) as first-line therapy for metastatic renal cell cancer: Pharmacokinetic data

Authors

Bjarnason GA; Knox J; Kollmannsberger CK; Soulieres D; Ernst DS; Zalewski P; Canil CM; Winquist E; Hotte SJ; North SA

Volume

28

Publisher

Elsevier

Publication Date

September 1, 2017

DOI

10.1093/annonc/mdx371.054

Conference proceedings

Annals of Oncology

ISSN

0923-7534

Contact the Experts team